<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594358</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00066787</org_study_id>
    <nct_id>NCT02594358</nct_id>
  </id_info>
  <brief_title>Caffeine in Amblyopia Study</brief_title>
  <acronym>CAS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective data on the visual acuity response in children treated by patching concurrently&#xD;
      treated with caffeine and estimate the magnitude of effect that might be seen in a randomized&#xD;
      trial (if no improvement in acuity is seen, this would be sufficient evidence to decide not&#xD;
      to conduct a randomized, double blind trial).&#xD;
&#xD;
      Collect prospective data on the tolerability of caffeine in two dosages as an adjuvant&#xD;
      treatment for amblyopia and provide limited data on its safety.&#xD;
&#xD;
      Evaluate the potential for a dietary intervention to enhance the acceptance and tolerability&#xD;
      of patching on the child and family.&#xD;
&#xD;
      Demonstrate recruitment potential of subjects to participate in a dietary intervention study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Could not recruit&#xD;
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantitative improvement in high resolution visual acuity measured at 3 meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>A multiquestion survey is adminsitered to the subjects specifically asking about side effects and quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Caffeine 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patching plus once daily caffeine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patching plus once daily caffeine for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING</description>
    <arm_group_label>Caffeine 20 mg</arm_group_label>
    <arm_group_label>Caffeine 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Amblyopia from strabismus and amblyopia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to caffeine&#xD;
&#xD;
          -  Diagnosis and/or treatment of attention deficit/hyperactivity disorder&#xD;
&#xD;
          -  Presence of an ocular cause for reduced visual acuity&#xD;
&#xD;
          -  Myopia with a special equivalent -6.00 diopters&#xD;
&#xD;
          -  Current vision therapy or orthoptics - any type&#xD;
&#xD;
          -  Ocular cause for reduced visual acuity&#xD;
&#xD;
          -  Prior intraocular or refractive surgery&#xD;
&#xD;
          -  History of narrow-angle glaucoma&#xD;
&#xD;
          -  Strabismus surgery planned within 16 weeks&#xD;
&#xD;
          -  Nystagmus per se does not exclude the subject if the above visual acuity criteria are&#xD;
             met&#xD;
&#xD;
          -  Known skin reactions to patch or bandage adhesives&#xD;
&#xD;
          -  Known allergy or intolerance to food dyes&#xD;
&#xD;
          -  Current treatment with topical atropine eyedrops&#xD;
&#xD;
          -  Menarche, pregnancy or lactation&#xD;
&#xD;
          -  Use of any of the following medications which may affect caffeine metabolism:&#xD;
             nafcillin, verapamil, fluvoxamine, ciprofloxacin and other fluoroquinolones,&#xD;
             modafinil, nafcillin, and omeprazole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael X Repka, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Michael Repka</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Caffeine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

